Alerta

BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA

Resumen de: MX2025012470A

Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subj ect.

BISPECIFIC ANTIBODIES THAT BIND CD3 AND THE GANGLIOSIDE NGCGM3

Resumen de: MX2026002768A

The present invention relates to the field of biotechnology and immuno-oncology. The present invention discloses bispecific antibodies comprising an antibody, antibody fragment or single chain variable fragment that recognise the ganglioside NGcGM3 in tumour cells and an antibody, antibody fragment or single chain variable fragment that recognise the antigen CD3 in human immune effector cells. These bispecific antibodies are characterised by their ability to mediate selective cytotoxicity in NGcGM3-positive tumour cells, and not in normal cells which may express the ganglioside and allow the recruitment of not only T lymphocytes, but also NKT cells. The bispecific antibodies of the present invention and the nucleic acids encoding the same are suitable for treating lymphoproliferative disorders and solid tumours that express NGcGM3.

TREATMENT OF NON SMALL CELL LUNG CANCER WITH ALECTINIB

Nº publicación: MX2026002326A 01/04/2026

Solicitante:

F HOFFMANN LA ROCHE AG [CH]
F. HOFFMANN-LA ROCHE AG

Resumen de: MX2026002326A

The present invention relates to a method of treating anaplastic lymphoma kinase (ALK)- positive non-small cell lung cancer (NSCLC), comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject has resected stage Ib ALK-positive NSCLC with a tumour greater or equal to 4cm to stage IIIa ALK-positive NSCLC.